Generic drug
Bosentan price, strengths & recalls
Bosentan has no weekly pharmacy acquisition cost. 3 manufacturers make it. Its official label last changed on November 17, 2025.
GenericBosentan price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 32 mg tablet for oral suspension | Not priced this week | |||
Supply status: shortages & recalls
What people paid for Bosentan
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use BOSENTAN TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for BOSENTAN TABLETS FOR ORAL SUSPENSION. BOSENTAN tablets, for oral suspension Initial U.S. Approval: 2001
WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETALTOXICITY
Because of the risks of hepatotoxicity and birth defects, bosentan tablets for oral suspension is available only through a restricted program called the Bosentan REMS Program. Under the Bosentan REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions (5.3)].
Hepatotoxicity
In clinical studies, bosentan caused at least 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly [see Dosage and Administration (2.4), Warnings and Precautions (5.1)]. In the post marketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (> 12 months) therapy with bosentan in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of bosentan in these cases could not be excluded.
In at least one case, the initial presentation (after > 20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of bosentan. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping bosentan with a rise of aminotransferases accompanied by signs or symptoms of liver dysfunction [see Dosage and Administration (2.4)].
Elevations in aminotransferases require close attention [see Dosage and Administration (2.4)]. Bosentan should generally be avoided in patients with elevated aminotransferases (>3xULN) at baseline because monitoring for hepatotoxicity may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥2xULN, treatment with bosentan should be stopped. There is no experience with the reintroduction of bosentan in these circumstances.
Embryo-Fetal Toxicity
Bosentan is likely to cause major birth defects if used by pregnant females based on animal data [see Warnings and Precautions (5.2), Use in Specific Populations (8.1)]. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for one month after stopping bosentan, females of reproductive potential must use two reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization, in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan [see Drug Interactions (7.2)]. Obtain monthly pregnancy tests.
WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY
See full prescribing information for complete boxed warning.
Bosentan tablets for oral suspension are available only through a restricted distribution program called the Bosentan REMS Program because of these risks (5.3):
Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with bosentan (5.1).
Measure liver aminotransferases prior to initiation of treatment and then monthly (2.1, 5.1).
Discontinue bosentan if aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin ≥2xULN (2.4, 5.1).
Based on animal data, bosentan is likely to cause major birth defects if used during pregnancy (4.1, 5.2, 8.1).
Must exclude pregnancy before and during treatment (2.1, 4.1, 8.1).
To prevent pregnancy, females of reproductive potential must use two re-liable forms of contraception during treatment and for one month after stopping bosentan (4.1, 5.2, 8.1).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 2 approved generic applications on the market
Bosentan questions
Is bosentan in shortage?
No shortage is reported for bosentan right now. We check the national shortage list every day.
Has bosentan been recalled?
No recalls are on record for bosentan.
When did the bosentan label last change?
The official label was last updated on November 17, 2025 (version 7). See what changed.
Talk about bosentan
No comments yet. Questions, tips, what worked for you - start the conversation.